Proteomics International Laboratories is escalating its expansion into the European market after appointing Netherlands-based sales agency Growth Medics to promote its “PromarkerD” predictive test for diabetic kidney disease (DKD).
Management says there are more than 61 million adults across Europe living with type 2 diabetes, leading to healthcare costs of about €176 billion (AU$285.36 billion) and additional medical complications for patients.
